Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Debt (2018 - 2023)

Protagonist Therapeutics' Total Debt history spans 6 years, with the latest figure at $10000.0 for Q2 2023.

  • For Q2 2023, Total Debt fell 87.5% year-over-year to $10000.0; the TTM value through Jun 2023 reached $10000.0, down 87.5%, while the annual FY2022 figure was $69000.0, 92.32% down from the prior year.
  • Total Debt for Q2 2023 was $10000.0 at Protagonist Therapeutics, down from $22000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $11.4 million in Q2 2021 and bottomed at $10000.0 in Q2 2023.
  • The 5-year median for Total Debt is $1.0 million (2019), against an average of $1.8 million.
  • The largest annual shift saw Total Debt surged 1036.19% in 2021 before it crashed 99.3% in 2022.
  • A 5-year view of Total Debt shows it stood at $1.3 million in 2019, then soared by 116.48% to $2.7 million in 2020, then tumbled by 67.09% to $899000.0 in 2021, then plummeted by 92.32% to $69000.0 in 2022, then tumbled by 85.51% to $10000.0 in 2023.
  • Per Business Quant, the three most recent readings for PTGX's Total Debt are $10000.0 (Q2 2023), $22000.0 (Q1 2023), and $69000.0 (Q4 2022).